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Background: Polycystic Ovary Syndrome (PCOS) is defined by two out of the following three criteria being met:
oligo- or anovulation, hyperandrogenism, and polycystic ovaries. Affected women are often obese and insulin
resistant. Although the etiology is still unknown, members of the Transforming Growth Factor β (TGFβ) family,
including Bone Morphogenetic Proteins (BMPs) and anti-Müllerian hormone (AMH), have been implicated to play a
role. In this pilot study we aimed to measure serum BMP levels in PCOS patients.
Methods: Twenty patients, fulfilling the definition of PCOS according to the Rotterdam Criteria, were randomly
selected. Serum BMP2, -4, -6 and −7 levels were measured using commercially available BMP2, BMP4, BMP6 and
BMP7 immunoassays.
Results: Serum BMP2, serum BMP4 and serum BMP6 levels were undetectable. Three patients had detectable
serum BMP7 levels, albeit at the lower limit of the standard curve.
Conclusions: BMP levels were undetectable in almost all patients. This suggests that with the current sensitivity of
the BMP assays, measurement of serum BMP levels is not suitable as a diagnostic tool for PCOS.
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Polycystic Ovary Syndrome (PCOS) is one of the most
common endocrine disorders in premenopausal women
[1]. The diagnosis is based on two of the following three
criteria being met: hyperandrogenism, oligo- or anovu-
lation, and polycystic ovaries [2]. PCOS is the most fre-
quent cause of infertility in women in their reproductive
years, affecting 6-8% of women in the general population
worldwide. Besides the reproductive phenotype, women
with PCOS often display a metabolic phenotype: 38-88%
of women with PCOS are obese with a characteristic ab-
dominal distribution of fat and up to 70% are insulin re-
sistant and some are found to have type II Diabetes
Mellitus [3,4]. Although the etiology is unknown, it is
generally agreed that elevated androgens are the main
culprit of the syndrome [5]. The increased ovarian an-
drogen production may result from the increased GnRH
pulsatility, which leads to increased LH secretion in* Correspondence: j.visser@erasmusmc.nl
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distribution, and reproduction in any mediumfavor of FSH [6]. Combined with the advanced LH
responsiveness of small growing follicles, this causes
increased androgen production, which is further en-
hanced by the elevated insulin levels. This abnormal
endocrine environment has been suggested to suppress
FSH action and causing follicular arrest [7]. In addition,
intrinsic alterations in folliculogenesis have been pro-
posed to contribute to the failure in dominant follicle se-
lection in PCOS [7]. Ovarian growth factors, such as
members of the transforming growth factor β (TGFβ)
family, play important roles in follicle recruitment,
follicle selection, and FSH responsiveness. Studies
performed predominantly in rodents showed that the
various Bone Morphogenetic Proteins (BMPs) are
expressed in a cell-specific manner in the ovary, and dis-
play spatial and temporal changes in expression depend-
ing on the stage of follicular development [8-10]. BMP15
is specifically expressed by oocytes [11], also in ovine,
bovine and human, whereas BMP6 has an oocyte/
granulosa cell expression pattern in various species.
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growth factors with mRNA expression detectable from the
small preantral stage onwards in rats [8,12]. However, in
mouse, human and bovine ovaries also granulosa cell ex-
pression of BMP4 mRNA has been reported [13-15]. Anti-
Müllerian hormone (AMH) is specifically expressed by the
granulosa cells of small growing follicles in various species
including human [16]. BMPs and AMH differently regu-
late FSH responsiveness and FSH-induced steroidogenesis,
hence it has been suggested that these factors may con-
tribute to the pathogenesis of PCOS.
Several studies have shown that serum AMH levels are
elevated in women with PCOS. These elevated levels re-
flect the increased antral follicle count (AFC) in PCOS. In
addition, AMH production per granulosa cell appears to
be increased [17-19]. Whether serum BMP levels are al-
tered in women with PCOS is unknown.
Given the role of BMPs in FSH-responsiveness and
FSH-induced steroidogenesis, we investigated whether
serum BMP levels could be used as a diagnostic tool for
PCOS.
Materials and methods
Patients
Twenty normogonadotrophic normoestrogenic dysovula-
tory patients, fulfilling the definition of PCOS according
to the Rotterdam Criteria [2], were selected from the
Rotterdam PCOS cohort, which comprises of PCOS pa-
tients attending our fertility clinic between 1997 and
2011. Standardized initial screening (clinical investigation,
transvaginal ultrasound, and fasting blood withdrawal) was
performed on a random cycle day between 0900 and 1100
h, irrespective of the interval between blood sampling and
the preceding bleeding, as previously described [20]. Bio-
chemically hyperandrogenemia was defined as an elevated
(>4.5) free androgen index (testosterone × 100/ SHBG)
and clinical hyperandrogenemia was defined as a Ferriman
Gallway score > 8. Polycystic ovaries were defined as 12 or
more follicles (measuring 2–9 mm) per ovary, and/or an
ovarian volume above 10 ml [21]. Endocrine screening in-
cluded assessment of serum AMH, testosterone and SHBG
levels and were determined previously [22,23]. Briefly,
blood samples were stored at −20 C until further assess-
ments were made. Serum hormone levels were assessed at
the time patients were originally seen. Serum SHBG was
measured by luminescence-based immunometric assays
(Immulite 2000, Diagnostic Products Corp., Los Angeles,
CA). Serum testosterone was measured using a RIA (Diag-
nostic Products Corp.). AMH levels were measured col-
lectively in samples stored, using an in-house AMH ELISA
assay (commercially available through Beckman Coulter,
Woerden, The Netherlands). Approval by the local medical
ethics committee was obtained and all participants have
given informed consent.BMP measurements
Serum BMP2, -4 and −7 levels were measured using a
Quantikine BMP2, BMP4 and BMP7 Immunoassay (R&D
Systems, Minneapolis, MN, USA). Serum BMP6 levels
were measured using a human BMP6 DuoSet ELISA
Development kit (also R&D Systems). All samples were
measured in single measurements according to the manu-
facturer’s instructions. For BMP2 the detection limit of the
assay was between 62.5 pg/mL and 4000 pg/mL. For
BMP4 and −7 the detection limits of the assay were be-
tween 31.2 pg/mL and 2000 pg/mL. For BMP6 the detec-
tion limit of the assay was between 78.13 pg/mL and 1000
pg/mL. Controls with low, medium and high concentra-
tions for BMP2 (207–558 pg/mL, 759–1509 pg/mL,
1670–3061 pg/mL), BMP4 (89–140 pg/mL, 512–780
pg/mL, 958–1468 pg/mL) and BMP7 (180–248 pg/mL,
502–698 pg/mL, 1010–1442 pg/mL) were provided by
R&D Systems. For BMP6 controls were not available. All
samples where measured in one plate per assay.
Results
PCOS patient characteristics are given in Table 1. Serum
BMP7 was detectable in only three of the 20 PCOS patients
(Table 1), albeit at very low levels. Serum BMP2, -4 and −6
were undetectable in all PCOS patients (Table 1). Extending
the standard curve with an extra dilution step, allowed the
detection of serum BMP4 in only one patient, whereas
BMP2 and −6 remained undetectable. In contrast, serum
AMH levels were easily detectable at an average concentra-
tion of 20.9 ng/mL. For four patients AMH levels were un-
known, because data and serum of these patients were
collected before AMH measurements were routinely deter-
mined in the clinic.
Discussion
In this pilot study, BMP2, -4 and −6 were undetectable
in all PCOS patients. BMP7 was detectable in only three
patients, but with levels close to the lower limit of the
standard curve. The addition of an extra lowest point to
the standard curve did not improve the measurement of
BMPs. The patients with discernible serum BMP7 values
did not show a consistent pattern with respect to FAI,
BMI or AFC. Since the BMPs studied were undetectable
in nearly all of the twenty PCOS patients, and therefore
could not be used to further distinguish the heteroge-
neous PCOS population, we did not attempt to analyze a
larger number of PCOS patients nor a cohort of normo-
ovulatory women as controls.
In a recent study by Son et al. [24], serum BMP4 levels
were measured in male and female subjects and shown
to be associated with adiposity, insulin resistance and
the metabolic syndrome. BMP4 levels ranged between
0.63 ± 0.41 pg/mL and 9.91 ± 4.48 pg/mL and were de-
termined with the same assay as in our study. Since the
Table 1 Clinical characteristics and BMP levels in PCOS women
Patient Age (years) FAI BMI (kg/m2) AFC AMH (ng/ml) BMP2 (pg/mL) BMP4 (pg/mL) BMP6 (pg/mL) BMP7 (pg/mL)
1 28 1.63 21.6 42 13.2 - - - -
2 28 0.92 22 55 28.7 - - - -
3 30 1.68 20 47 15.8 - - - -
4 20 0.62 22.2 50 20 - - - -
5 30 1.03 19.6 59 31.9 - - - 57.60
6 30 7.93 24.6 40 30.9 - - - -
7 23 5.53 19.4 73 28.5 - - - -
8 22 5.70 21.1 54 n.d. - - - -
9 20 5.50 24.7 62 n.d. - - - 43.88
10 25 13.27 24.2 48 26.6 - - - -
11 25 1.50 30.4 32 6.5 - - - -
12 31 1.75 44.1 77 23.5 - - - -
13 31 1.42 30.1 41 8.8 - - - -
14 24 1.21 31.8 44 13.6 - - - -
15 26 13.50 30.1 160 n.d. - - - -
16 25 15.13 32.3 153 37 - - - 42.38
17 27 19.20 32.7 110 n.d. - - - -
18 27 9.20 32.0 103 17.8 - - - -
19 28 9.50 34.3 101 n.d. - - - -
20 23 26.57 43.2 91 26.6 - - - -
FAI: Free Androgen Index; BMI: Body Mass Index; AFC: Antral Follicle count.
n.d.: not determined.
- : below detection limit of the assay.
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31.2 pg/mL, these values are well below the standard
curve, and therefore it is unclear whether the results of
Son et al. have any practical implications. Associations
of BMP4 values that far below the detection range are
weak at best.
Conflicting results have also been reported for BMP2 and
BMP7. Using the same assay, one study showed that serum
BMP2 levels were undetectable in patients with femoral
fractures [25], whereas in another study, serum BMP2
and −7 levels [10,26,27] could be detected in patients with
ankylosing spondylitis, arthritis and healthy subjects [28].
Also, in the latter study BMP levels were near or below the
detection range of the assay. In agreement, other studies
have also shown that serum BMP7 levels are often below
or close to the standard curve of the assay [29,30].
All women used in this study had polycystic ovaries
and in accordance with these results increased AMH
levels. An explanation for the undetectable serum BMP
levels in this study could be that BMPs are not secreted
by the human ovary, although it has been reported that
BMP2, -4, -6 and 7 are expressed by the human ovary
[9]. This explanation may not be likely since this would
be in contrast to other ovarian expressed TGFβ familymembers that are secreted, such as AMH, Inhibin B and
Activin A [18,31]. Alternatively, BMP immunoreactivity
may not have been preserved. Prolonged storage and re-
peated freeze/thawing of the samples did not affect the
immunoreactivity of AMH, a family member of BMPs,
but an effect on BMP immunoreactivity cannot be ruled
out. However, based on the studies mentioned above
and our own study, we prefer to suggest an alternative
reason, namely that the current available BMP assays are
not sensitive enough to detect BMP ligands in the circu-
lation of human subjects. Therefore, more sensitive
assays are necessary to determine whether serum BMP
levels could be used as an additional diagnostic tool in
PCOS and other metabolic diseases.
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